Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study.
Kristian ReichJ SullivanP ArenbergerS JazayeriUlrich MrowietzMatthias AugustinBoni E ElewskiR YouP RegnaultJ A FruehPublished in: The British journal of dermatology (2020)
Secukinumab demonstrated strong and clinically meaningful efficacy for up to 2·5 years in nail psoriasis, with significant sustained QoL improvements and a favourable safety profile.